June 9, 2020 / 12:04 PM / 24 days ago

BRIEF-Revolution Medicines Announces Dosing Of First Patient In Phase 1B Combination Study Of RMC-4630 And AMG 510

June 9 (Reuters) - Revolution Medicines Inc:

* REVOLUTION MEDICINES ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 1B COMBINATION STUDY OF RMC-4630 AND AMG 510 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below